Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) released its earnings results on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $0.03, Zacks reports. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%.
Fresenius SE & Co. Stock Performance
Shares of Fresenius SE & Co. stock traded up $0.85 during trading on Wednesday, reaching $14.46. The company’s stock had a trading volume of 27,484 shares, compared to its average volume of 167,317. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The firm has a market cap of $32.58 billion, a PE ratio of 18.30 and a beta of 0.63. Fresenius SE & Co. has a 52 week low of $10.33 and a 52 week high of $17.60. The business’s 50-day moving average price is $12.89 and its 200-day moving average price is $12.86.
Analyst Ratings Changes
A number of brokerages recently commented on FSNUY. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Finally, Citigroup reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday, October 28th. Three analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company has an average rating of “Buy”.
View Our Latest Research Report on FSNUY
About Fresenius SE & Co.
Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.
Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.
Read More
- Five stocks we like better than Fresenius SE & Co.
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
- Washington Made a $2 Billion Quantum Bet, But Can Either ETF Match It?
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
